Hepatoxicity of new antiretrovirals: A systematic review
- 1 April 2013
- journal article
- review article
- Published by Elsevier BV in Clinics and Research in Hepatology and Gastroenterology
- Vol. 37 (2), 126-133
- https://doi.org/10.1016/j.clinre.2013.02.008
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Pooled week 96 results of the phase III DUET‐1 and DUET‐2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interestHIV Medicine, 2012
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialThe Lancet, 2011
- Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfectionHIV Medicine, 2011
- Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trialsJournal of Antimicrobial Chemotherapy, 2010
- Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshopHepatology, 2010
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir PharmacokineticsAntimicrobial Agents and Chemotherapy, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008